Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).
Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC). A Multicenter Single Arm Open Label Phase II Trial.
Sponsor: Swiss Cancer Institute
This PHASE2 trial investigates Lung Cancer and Small Cell Lung Cancer and is currently ongoing. Swiss Cancer Institute leads this study, which shows 14 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
14 versions recorded-
Nov 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Sep 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
Oct 2024 — Aug 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 9 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Apr 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE2
-
Feb 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2022 — Feb 2023 [monthly]
Recruiting PHASE2
-
Sep 2021 — Sep 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Swiss Cancer Institute
For direct contact, visit the study record on ClinicalTrials.gov .